Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) on Tuesday announced the launch of the 2017 CDER Office of Pharmaceutical Quality (OPQ) Staff Experiential Learning Site Visit Program, which is meant to help OPQ staff learn more about industry’s drug development and manufacturing processes.
The program, which aims to bring groups of OPQ staff to observe operations of commercial manufacturing, pilot plants and pharmaceutical testing over a one- to two-day period, is designed to offer firsthand learning opportunities to improve staffers’ understanding of the pharmaceutical industry and its operations, as well as of the challenges that impact drug development.
OPQ has identified a number of areas of particular interest to its staff, including:
Selection of potential facilities for the program will be based on these priorities, FDA says, as well as the facility’s current regulatory status with FDA, and based on consultation with FDA district offices.
All travel expenses associated with this program will be the responsibility of OPQ, so selection of the sites that can participate will be based on the availability of funds and resources, and OPQ says it will not provide financial compensation to the sites as part of this program.
The program will allow participating sites to benefit by having an opportunity to showcase their technologies and manufacturing processes.
Companies interested in offering a site visit or learning more about this site visit program should respond by submitting a proposal to Janet Wilson at CDEROPQSiteVisits@fda.hhs.gov.
Site Visit Training Program for Office of Pharmaceutical Quality Staff; Information Available to Industry
Tags: OPQ inspections, FDA inspection training, CDER inspections